This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.
The transcription factor RORγ plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is, therefore, an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered RORγ modulators into clinical trials.
Some studies found RORγ to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic RORγ agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression
The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for the treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.